The fallback is now the traditional chemotherapeutic use of bisantrene using the RC220 formulation. This has real value beyond AML, but is relatively minor compared to the FTO and cardioprotection opportunities.
Don't presume anything in regards not being able to sell the same drug for different indications to different companies for the same geography. I put a great deal of effort into this question before I left RAC.
FTO is probably easier to validate than cardioprotection, but if you run the right trials you can validate both at the same time.
The highest return on equity for small biotechs is achieved after Phase 2 validation. Race is a little more complex as we have a drug with multiple major opportunities, rather than a pipeline of different drugs. Bisantrene is probably closer to something like aspirin with its multiple different uses than the usual oncology drug. Makes for a complex commercialisation strategy.
Yes like you I hope we get an extensive update with all the details required for us to understand the preclinical, clinical and commercial strategy.
General Comments / Chat, page-8661
-
- There are more pages in this discussion • 2,896 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.78 |
Change
-0.040(2.20%) |
Mkt cap ! $302.5M |
Open | High | Low | Value | Volume |
$1.81 | $1.82 | $1.76 | $132.8K | 74.40K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 170 | $1.77 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.78 | 2 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 4000 | 1.755 |
3 | 12714 | 1.750 |
1 | 3000 | 1.740 |
1 | 1405 | 1.720 |
4 | 25414 | 1.700 |
Price($) | Vol. | No. |
---|---|---|
1.780 | 3781 | 1 |
1.830 | 7500 | 1 |
1.840 | 1000 | 1 |
1.850 | 5222 | 1 |
1.880 | 2351 | 1 |
Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |